Methylprednisolone hemisuccinate

Generic Name: Methylprednisolone hemisuccinate

Brand Names: Solu-medrol

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₄O_₈

CAS Number: 2921-57-5

Unique Ingredient Identifier: 5GMR90S4KN

Background: A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.

Associated Conditions: Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis

Associated Therapies: Palliative Treatment

Clinical Trials

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002)

Phase 1

Terminated

Conditions: Rheumatoid Arthritis

Interventions: Biological: MK-8808
Drug: Methotrexate
Biological: MabThera® (rituximab)
Drug: Methylprednisolone
Biological: Rituxan® (rituximab)
Drug: Acetaminophen
Drug: Loratadine

First Posted Date: 2011-07-11

Last Posted Date: 2016-07-20

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 100

Registration Number: NCT01390441

A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: rituximab
Drug: methotrexate
Drug: methylprednisolone
Drug: acetaminophen
Drug: antihistamine

First Posted Date: 2011-06-27

Last Posted Date: 2017-08-01

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 351

Registration Number: NCT01382940

Locations: 🇺🇸
Clnical & Translational Reseach Center for Alabama, PC, Tuscaloosa, Alabama, United States
🇺🇸
ArthroCare, Arthritis Care; and Research P.C., Gilbert, Arizona, United States
🇺🇸
Catalina Pointe Rheumatology, Tucson, Arizona, United States

and more 81 locations

Gene Therapy for Fanconi Anemia

Phase 1

Terminated

Conditions: Fanconi Anemia

Interventions: Procedure: Bone Marrow Aspiration
Biological: Filgrastim
Biological: Genetically Engineered Hematopoietic Stem Progenitor Cells
Other: Laboratory Biomarker Analysis
Procedure: Leukapheresis
Drug: Methylprednisolone
Drug: Plerixafor
Drug: Prednisone

First Posted Date: 2011-04-07

Last Posted Date: 2024-05-17

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 3

Registration Number: NCT01331018

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Drug: Rituximab
Drug: Imatinib
Drug: VSLI
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Solu-Medrol
Drug: Mesna
Drug: Methotrexate
Drug: Ara-C
Drug: G-CSF
Drug: Pegfilgrastim
Drug: Dexamethasone

First Posted Date: 2011-03-22

Last Posted Date: 2022-09-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT01319981

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Infliximab as Induction Therapy in Early Rheumatoid Arthritis (IDEA)

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Infliximab
Drug: Methylprednisolone
Drug: Methotrexate
Dietary Supplement: Folic acid

First Posted Date: 2011-03-04

Last Posted Date: 2019-11-01

Lead Sponsor: University of Leeds

Target Recruit Count: 112

Registration Number: NCT01308255

Locations: 🇬🇧
Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom

Cyclic Oral Methylprednisolone Trial in Multiple Sclerosis

Phase 2

Completed

Conditions: Progressive Multiple Sclerosis

Interventions: Drug: methylprednisolone

First Posted Date: 2011-03-01

Last Posted Date: 2013-07-11

Lead Sponsor: Rigshospitalet, Denmark

Target Recruit Count: 30

Registration Number: NCT01305837

Locations: 🇩🇰
Scleroseklinikken, Rigshospitalet, Copenhagen, Denmark

Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)

Phase 3

Completed

Conditions: Community Acquired Respiratory Disease Syndrome

Interventions: Drug: Inactive Substance
Drug: Methylprednisolone

First Posted Date: 2011-01-25

Last Posted Date: 2020-10-08

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 584

Registration Number: NCT01283009

Locations: 🇺🇸
VA Western New York Healthcare System, Buffalo, NY, Buffalo, New York, United States
🇺🇸
VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸
Salem VA Medical Center, Salem, VA, Salem, Virginia, United States

and more 27 locations